Friday Pop Quiz 9/6/2024
A 35-year-old woman presents to clinic with the skin lesions (shown) and joint pain. She was previously well controlled on guselkumab, but has flared since her dog was diagnosed with cancer. She has previously failed various treatments including topical steroids, methotrexate, narrow-band UVB, adalimumab, ixekizumab, and etanercept. She developed transaminitis and hepatic steatosis in response t …
A 35-year-old woman presents to clinic with the skin lesions (shown) and joint pain. She was previously well controlled on guselkumab, but has flared since her dog was diagnosed with cancer. She has previously failed various treatments including topical steroids, methotrexate, narrow-band UVB, adalimumab, ixekizumab, and etanercept. She developed transaminitis and hepatic steatosis in response t … 
Next Steps in Derm and the Journal of Drugs in Dermatology, in partnership with the Dermatology Education Foundation (DEF) and Physicians Resources, interviewed Dr. April Armstrong (Professor of Dermatology and Associate Dean for Clinical Research at the Keck School of Medicine at USC) on applying the psoriasis guidelines established by the American Academy of Dermatology and the National Psor … 
Verrucous psoriasis (VP) is a rare histologic variant of psoriasis. To date, fewer than 40 cases have been reported, with pediatric cases representing an exceedingly small fraction. Treatment options are limited, and the disease is often refractory to conventional methods. Herein, JDD authors Samantha Sherkin OMS-IV, Christian Summa OMS-IV, David Crasto DO, Zackary Whitney DO, Lazlo Karai MD PhD,� … 
Dermatologists are prescribing oral glucocorticoids for psoriasis despite awareness of risks of life-threatening generalized pustular psoriasis (GPP) and erythrodermic psoriasis (EP). A recent survey of dermatologists published in the Journal of Drugs in Dermatology found 18% of respondents occasionally prescribe oral glucocorticoids to patients with psoriasis, typically 1-5% of the time. Those wh … 
The April 2022 issue of the Journal of Drugs in Dermatology (JDD) includes the perfect blend of original articles, case reports, and editorials. With topics ranging from injectable fillers, botulinum toxin in hidradenitis suppurativa, cannabis and cannabinoid product use, to psoriasis, melasma, onychomycosis and everything in between, we share this month’s issue highlights straight from the JDD … 